Cedars-Sinai Cancer has launched a Clinical and Regulatory Sciences Graduate Certificate Program, which begins in the fall of 2022.
Ju Dong Yang was named medical director of the Liver Cancer Program at Cedars-Sinai Cancer Center.
Researchers at Cedars-Sinai Cancer and Johns Hopkins University discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice.
Alicia M. Terando was named the San Gabriel Valley regional medical director for surgical oncology at Cedars-Sinai Cancer at the Huntington Cancer Center.
Researchers from Cedars-Sinai Cancer analyzed patient samples and studies conducted in animal models to identify a novel role for the IL-27 signaling pathway in hepatocellular carcinoma.
Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a study led by Cedars-Sinai Cancer investigators.
Research from Cedars-Sinai Cancer showed that a combination of androgen deprivation therapy plus pelvic lymph node radiation kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years.
Although there are more than 11 million LGBTQ+-identifying individuals in the U.S., this population remains “invisible in the research”—presenting a problem for cancer centers trying to better serve their catchment areas, said Zul Surani, associate director of community outreach and engagement at Cedars-Sinai Cancer.
B.J. Rimel, associate professor of obstetrics and gynecology at Cedars-Sinai Cancer at the Cedars-Sinai Medical Center, has been named medical director for the Cancer Clinical Trials Office.
